Apogee Therapeutics Announces Positive Interim Results From Phase 1B Trial of Zumilokibart (Apg777), Its Potentially Best-in-Class Anti-Il-13 Antibody, in Patients With Mild-to-Moderate Asthma and Highlights 2026 Anticipated Milestones and Outlook
Apogee Therapeutics Announces Positive Interim Results From Phase 1B Trial of Zumilokibart (Apg777), Its Potentially Best-in-Class Anti-Il-13 Antibody, in Patients With Mild-to-Moderate Asthma and Highlights 2026 Anticipated Milestones and Outlook
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.